Bill Carson, M.D. is the Chairman of the Board of Otsuka Pharmaceutical Development & Commercialization, Inc. and was the President & CEO from 2010 through 2019.
Since his appointment in 2010 as the President & CEO, he led the development efforts of compounds in neuroscience, cardio-renal, and oncology, and was instrumental in the development and registration of ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension and SAMSCA® (tolvaptan).
He joined Otsuka in 2002 as a board-certified psychiatrist and served as OPDC’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During his career at Otsuka and earlier at Bristol-Myers Squibb (BMS), he was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole).
He received an A.B. degree in history and science from Harvard University and an M.D. degree from Case Western Reserve University.